Moderna MRNA 深 沪
已收盘 12-19 16:00:00 美东时间
33.68
+2.730
+8.82%
华盛通- 最 高34.25
- 今 开31.39
- 成交量 1387.05万股
- 最 低 23.92
- 昨 收 30.95
- 总市值 134.05亿
- 52周最高 48.92
- 市盈率 静 1.19
- 换手率 3.49%
- 52周最低 22.28
- 委 比 -22.45%
- 总股本 3.98亿
- 历史最高 497.49
- 量 比 1.36
- 振 幅 33.38%
- 历史最低 1.10
- 每 手 1
- 风险率 5.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.
12-13 02:51
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
12-12 02:39
2025年新型疗法：管线增长加速，中国力量崛起
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
12-10 11:45
Silver Soars Past $58, Bitcoin-Strategy Bloodbath Deepens: What's Moving Markets Monday?
Wall Street kicked off December with stocks slightly easing after a strong late-November rally, as rising global bond yields and sharp moves in commodities and crypto set a more cautious tone for equity traders.
12-02 02:25
First-Ever Human H5N5 Case Turns Fatal In Washington State
Washington reports world's first fatal human H5N5 bird flu case; officials say risk to public remains low, monitoring continues closely.
11-23 02:07
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains
Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side effects.
11-21 23:48
2025年生物技术公司“死亡名单”
庆祝成功重要，看见失败同样重要。 生物技术公司“死亡名单”系列被媒体从2023年做到了2025年。 令人遗憾的是，任何一家生物科技公司关闭，意味着将...
11-19 15:37
Merck Makes Big Bet On Flu Protection With Cidara Buyout
Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.
11-14 22:32
明星疫苗，集体失色
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：药闻社） 在新冠疫情之后，整个疫苗行业进入深度调整期。 不仅是新冠相关产...
11-11 21:03
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand declines.
11-07 01:29
